These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 7602345

  • 1. Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
    Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD.
    J Clin Oncol; 1995 Jul; 13(7):1572-7. PubMed ID: 7602345
    [Abstract] [Full Text] [Related]

  • 2. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
    Wenhui Z, Shuo L, Dabei T, Ying P, Zhipeng W, Lei Z, Xiaohui H, Jingshu G, Hongtao S, Qingyuan Z.
    Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
    [Abstract] [Full Text] [Related]

  • 3. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
    Byrne MJ, Gebski V, Forbes J, Tattersall MH, Simes RJ, Coates AS, Dewar J, Lunn M, Flower C, Gill PG, Stewart J.
    J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
    [Abstract] [Full Text] [Related]

  • 4. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
    Nomura Y, Tashiro H, Hisamatsu K, Toi M.
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
    [Abstract] [Full Text] [Related]

  • 5. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
    Muss HB, Case LD, Atkins JN, Bearden JD, Cooper MR, Cruz JM, Jackson DV, O'Rourke MA, Pavy MD, Powell BL.
    J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
    [Abstract] [Full Text] [Related]

  • 6. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.
    Bonomi P, Gale M, Von Roenn J, Anderson K, Johnson P, Wolter J, Economou S.
    Semin Oncol; 1988 Apr; 15(2 Suppl 1):26-33. PubMed ID: 3368797
    [Abstract] [Full Text] [Related]

  • 7. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment.
    Søreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S.
    Eur J Surg Oncol; 1992 Apr; 18(2):112-8. PubMed ID: 1582503
    [Abstract] [Full Text] [Related]

  • 8. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC, Crommelin MA, Repelaer van Driel OJ, Tutein Nolthenius-Puylaert MC, Vreugdenhil G, Coebergh JW.
    Ned Tijdschr Geneeskd; 1998 Aug 01; 142(31):1772-8. PubMed ID: 9856143
    [Abstract] [Full Text] [Related]

  • 9. Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PgR and AR) in patients with primary breast cancer.
    Lundgren S, Søreide JA, Lea OA.
    Anticancer Res; 1994 Aug 01; 14(3B):1313-6. PubMed ID: 8067700
    [Abstract] [Full Text] [Related]

  • 10. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
    Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A.
    Breast Cancer Res Treat; 2010 Dec 01; 124(3):607-17. PubMed ID: 20127405
    [Abstract] [Full Text] [Related]

  • 11. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
    Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ.
    J Clin Oncol; 1992 Aug 01; 10(8):1284-91. PubMed ID: 1634918
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
    J Natl Cancer Inst; 2005 Sep 07; 97(17):1254-61. PubMed ID: 16145046
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
    Berns EM, Klijn JG, van Putten WL, de Witte HH, Look MP, Meijer-van Gelder ME, Willman K, Portengen H, Benraad TJ, Foekens JA.
    J Clin Oncol; 1998 Jan 07; 16(1):121-7. PubMed ID: 9440732
    [Abstract] [Full Text] [Related]

  • 17. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2008 Mar 20; 26(9):1404-10. PubMed ID: 18349391
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.